Hepatitis C medication coverage guidelines (Direct-acting antiviral medications for chronic HCV)
Customize your policy alerts
Sign up for Hawaii Department of Human Services Policy QI-1510 alerts
Get alerted when Policy QI-1510 changes without checking for updates manually.
Monitor payer policy activity
Coverage guidelines for prior authorization and medical necessity of FDA‑approved direct-acting antiviral medications for chronic hepatitis C infection for QUEST Integration Medicaid managed care plans in Hawaii.
This memorandum replaces prior memoranda ADM-1408, ADMX-1408, QI-1411, and QI-1411A and provides updated Medicaid guidance allowing prior authorization of Hepatitis C medications for Medicaid managed care plans per Act 20.
Coverage and Medical Necessity Criteria
Initial therapy inclusion criteria
Covered when ALL of the following are met
Exact sequencing: all criteria must be satisfied for coverage.
Ribavirin pregnancy safeguards and contraindications
Ribavirin-containing regimens are subject to the following requirements and contraindications:
Reporting exposures to the Ribavirin Pregnancy Registry is encouraged.
DAA medications are not eligible for coverage if any of the documented exclusions apply. Notable exclusions include: end stage renal disease on hemodialysis, and chronic decompensated liver disease defined as Child‑Pugh > 6 unless the patient is an active candidate for liver transplantation. Hepatocellular carcinoma is likewise excluded unless the patient meets the Milan criteria and is an active transplant candidate. Coverage may also be precluded by absolute contraindications to agents used in combination with DAAs (for example, absolute contraindications to peg‑interferon or ribavirin as listed in the contraindications appendix).
Ribavirin is contraindicated in women who are pregnant and in men whose female partners are pregnant due to risks of birth defects and fetal death. Prior authorization processes must ensure that ribavirin is not initiated in these situations and that the prescribing clinician documents appropriate pregnancy testing and contraception planning for women of childbearing potential and male patients with female partners.
Treatment requests for patients who meet any of the exclusions listed in this policy should be considered not covered unless an explicit exception applies. Examples include patients with decompensated liver disease (Child‑Pugh > 6) who are not active liver transplant candidates and patients with end stage renal disease on hemodialysis. Requests for these patients must include documentation supporting transplant candidacy or other exception criteria; absent that documentation, the request is subject to denial per the policy exclusions.
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required
Prior authorization is required for hepatitis C DAA medications for QUEST Integration Medicaid managed care members; health plans shall use these guidelines to determine authorization and coverage when all inclusion criteria are met and no listed exclusions apply.
Pregnancy testing and contraception requirement for ribavirin
Do not start ribavirin-containing therapy in a pregnant woman; prior authorization must ensure a negative pregnancy test immediately prior to initiation and a documented contraception plan for women of childbearing potential and male patients with female partners.
- Obtain and document a negative pregnancy test immediately prior to initiating ribavirin-containing therapy.
- Document a contraception plan: women of childbearing potential and male partners must use two forms of effective contraception during treatment and for at least 6 months after treatment.
- Perform and document routine monthly pregnancy tests during treatment and for 6 months after treatment when ribavirin is used.
Regimen selection per FDA and national guidelines
Select regimens and dosing according to FDA‑approved genotype‑specific treatment regimens (Appendix A) and national guidelines; regimen choice should consider genotype, cirrhosis status, and prior treatment experience.
- Follow Appendix A (FDA‑approved regimens) and referenced national guidelines (AASLD, VA) for regimen and duration decisions.
- Consider genotype, cirrhosis status, and prior treatment experience when selecting regimen and duration.
Not specified
No specific additional provider action is specified in this section.
Required clinical documentation for prior authorization
Provide required clinical documentation with the prior authorization request: baseline quantitative HCV RNA within the previous 3 months and documentation of liver disease severity or transplant candidacy when applicable.
- Baseline quantitative HCV RNA result within the previous 3 months of starting treatment.
- Documentation of liver disease severity: biopsy with Metavir F3–F4, FibroScan ≥ 9.5 kPa, radiologic imaging consistent with cirrhosis, or clinical evidence of cirrhosis.
- If applicable, documentation of active liver transplant candidacy.
Required pregnancy testing and counseling documentation
When prescribing ribavirin, document a negative pregnancy test immediately prior to initiation and counseling on contraception and pregnancy testing during and after therapy; report exposures to the Ribavirin Pregnancy Registry when applicable.
- Document that a negative pregnancy test was obtained immediately prior to starting ribavirin-containing therapy.
- Document counseling provided to the patient (and male patients regarding partner risk) on required contraception during treatment and for 6 months after completion, and on monthly pregnancy testing.
- Encourage reporting of pregnancy exposures to the Ribavirin Pregnancy Registry (1-800-593-2214) and Antiretroviral Pregnancy Registry for HCV/HIV-1 co-infected patients (1-800-258-4263).
Limitations/exclusions that may trigger non‑coverage
Coverage may be denied if any exclusion applies, including end stage renal disease on hemodialysis; chronic decompensated liver disease (Child‑Pugh > 6) unless the patient is an active transplant candidate; hepatocellular carcinoma unless meeting Milan criteria and an active transplant candidate; or absolute contraindications to agents combined with DAAs (including absolute contraindications to peg‑interferon or ribavirin).
- End stage renal disease on hemodialysis.
- Chronic decompensated liver disease defined as Child‑Pugh score > 6 (transplant candidate exception applies).
- Hepatocellular carcinoma not meeting Milan criteria or not an active transplant candidate.
- Absolute contraindications to medications used with DAA (e.g., absolute contraindications to peg‑interferon or ribavirin).
Ribavirin contraindication and pregnancy-related denial risk
Ribavirin is contraindicated in women who are pregnant and in men whose female partners are pregnant; failure to confirm negative pregnancy testing and contraception adherence may result in denial of coverage or contraindication‑based denial.
- Do not start ribavirin if the patient is pregnant or if the male patient has a pregnant female partner.
- Prior authorization requests lacking documentation of negative pregnancy testing immediately prior to initiation or lacking contraception/counseling documentation risk denial based on contraindication.
Key Clinical Thresholds and Documentation Timeframes
Clinical Background
Direct‑acting antivirals (DAAs) are FDA‑approved therapies for chronic hepatitis C virus (HCV) infection and are prescribed in genotype‑specific regimens. Treatment selection depends on HCV genotype/subtype, presence and severity of fibrosis or cirrhosis, prior treatment history, and transplant candidacy. The policy requires baseline documentation (including a quantitative HCV RNA within the prior 3 months and evidence of fibrosis/cirrhosis such as Metavir F3–F4, FibroScan >= 9.5 kPa, or radiologic/clinical signs of cirrhosis) and specifies that regimens follow FDA labeling and national guidance for genotype, cirrhosis status, and prior treatment experience.
Definitions and Scoring Systems
Policy Changes and Effective Dates
Policy effective date following administrative consolidation and update after Act 20 allowing Medicaid managed care plans to prior authorize Hepatitis C medications; memorandum replaces ADM-1408, ADMX-1408, QI-1411, and QI-1411A.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.